Aptar expands pharma manufacturing in Mumbai

Key highlights
  • Mumbai site will add local production of pMDI valves, breath‑actuated systems and multi dose nasal spray systems.
  • Manufacturing footprint in Mumbai increases to 11,300 m² with added molding capability alongside existing assembly operations.
  • Expanded operations were inaugurated on October 5, 2026, by the Aptar Board Chair and Executive Committee members.
  • Aptar has operated in India since 1998, adding a Rabale assembly facility in 2012, a Hyderabad CPG manufacturing site in 2020, and a Taloja pharma site in 2023.
Related project For subscribers
Milestones, plant data, involved companies (owners, investors, licensors, contractors) and news — kept up to date.
Aptar Pharma Taloja Inhalation Technologies Expansion · India
Operational / Completed
2026-10-05
2026-10-08

Expansion scope

The Mumbai site will add local production of several pharma inhalation technologies, including Aptar’s pressurized metered dose inhaler (pMDI) valve, breath‑actuated systems and multi dose nasal spray systems. The expansion adds molding capability to the site’s existing assembly operations.

Capacity and local role

With the investment, the Mumbai manufacturing footprint has increased to 11,300 m². Aptar says the broadened site role will support evolving customer needs and enhance local capability and supply resilience to serve customers in India and across Southeast Asia with greater proximity.

Timeline and network

Aptar established a commercial presence in Mumbai in 1998, opened a Rabale assembly facility in 2012 and a Hyderabad manufacturing site for CPG products in 2020. A state‑of‑the‑art pharma site opened in Taloja in 2023. The expanded Mumbai operations were inaugurated on October 5, 2026.

Strategic rationale

Company leadership framed the investment as part of a long‑term strategy to deepen engagement in India, citing the market’s dynamics and growth potential. Aptar noted India’s rapid urbanization, expanding healthcare access, and investments in manufacturing and digital infrastructure as drivers for further opportunity.

Source: Aptar

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

12 November 2026
Aptar Pharma adds Schedule II and III controlled-substance capabilities in Boonton

The New Jersey facility can handle, store, manufacture and test controlled substances for inhaled and nasal drug products.

26 October 2026
Aptar Pharma acquires PULMOTREE to add Kolibri non‑propellant liquid inhaler

Adds Kolibri NPLI platform to support complex inhaled therapies including biologics, and integrates formulation, device, regulatory and digital services for end‑to‑end development.

14 October 2026
Aptar Pharma gains CE marking for LuerVax and Spray Divider

CE marking for a LuerLock‑compatible intranasal device and optional Spray Divider that delivers two sequential sprays (200 µL, 500 µL), supporting vaccine development from early clinical to commercial.

14 September 2026
Aptar Pharma and Massachusetts General Hospital build predictive nose-to-brain delivery platform

Partners will create an integrated translational platform to quantify mechanisms, pathways and kinetics of nose-to-brain drug transport using in vitro, in vivo and computational tools.

11 September 2026
Aptar Pharma expands APF preservative-free pump production in Argentina

APF multidose preservative‑free pump line commissioned to serve Latin American markets, cutting lead times and improving local supply agility.